Resources & Evidence Contact us

130 Results:

Sort By:

Prolacta Bioscience celebrates Prematurity Awareness Month and World Prematurity Day by recognizing the contributions of breast milk donors, parents of premature infants, and the NICU teams who care for them

Type: Press Releases

Topic(s): 22-27 weeks (extremely premature) Company Donors Growth Long-Term outcomes

New study finds improved long-term neurodevelopmental outcomes for extremely premature infants fed Prolacta’s exclusive human milk diet (EHMD)

Type: Press Releases

Topic(s): Long-Term outcomes Neurodevelopmental Outcomes

Breaking data on the efficacy and cost-effectiveness of an exclusive human milk diet for premature infants to be presented at the American Academy of Pediatrics 2022 National Conference

Type: Press Releases

Topic(s): Company Conferences and Events Cost Savings / Cost Effectiveness

New peer-reviewed study finds vat pasteurization retains molecular structure of naturally occurring bioactive proteins in human donor milk, similar to raw breast milk

Type: Press Releases

Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Microbiome Pasteurization Quality & Safety

Prolacta Bioscience recognizes nurses caring for fragile infants every day throughout Neonatal Nurses Week and NICU Awareness Month

Type: Press Releases

Topic(s): Company

Prolacta Bioscience celebrated Breastfeeding Awareness Month by recognizing the commitment of NICU parents to their infants’ health

Type: Press Releases

Topic(s): Company Parents

Prolacta Bioscience Appoints Dr. Erin Hamilton Spence as Director of Clinical Education and Professional Development

Type: Press Releases

Topic(s): Company

Multiple peer-reviewed studies show Prolacta’s 100% human milk-based nutritional fortifiers reduce risk of life-threatening comorbidities in premature infants, compared to cow milk-based nutrition

Type: Press Releases

Topic(s): Bronchopulmonary Dysplasia (BPD) Clinical Studies Clinical Studies on Prolact/Humavant CR Company Growth Late-Onset Sepsis Necrotizing Entercolitis (NEC) Retinopathy of Prematurity (ROP)

Prolacta Bioscience introduces its first evidence-based feeding protocol for an exclusive human milk diet in the NICU

Type: Press Releases

Topic(s): Bronchopulmonary Dysplasia (BPD) Company Early Fortification Feeding Intolerance Feeding Protocols Growth Healthcare Professionals Late-Onset Sepsis Length of hospital stay Long-Term outcomes Necrotizing Entercolitis (NEC) Product Retinopathy of Prematurity (ROP)

Not finding the reference you’re looking for?

Use our main search field or email us at info@prolacta.com